Impact of regulatory interventions to restrict the combined use of renin-angiotensin system-acting agents: A Danish nationwide drug utilisation study
Research output: Contribution to journal › Journal article › Research › peer-review
Documents
- Fulltext
Final published version, 575 KB, PDF document
This study aimed to evaluate the impact of the risk minimisation measures issued by the European Medicines Agency in 2014 to restrict the combined use of renin-angiotensin system (RAS) agents in Denmark. Data from the Danish National Prescription Registry covering all medications dispensed during January 2008-December 2018 was used. The outcome was monthly prevalence of patients co-dispensed RAS-acting agents. Autoregressive integrated moving average interrupted time series regression was used to evaluate dispensing trends. The prevalence of patients co-dispensed RAS-acting agents decreased from 0.01% to 0.0003%. Pre-intervention trend was declining and further decreased with an additional -0.45 (95% confidence interval -0.66, -0.25) co-dispensing per million population after the intervention. Overall, the intervention had minimal impact on the combined use of RAS-acting agents. However, as the combined use of RAS-acting agents is low, further interventions to restrict the combined use of RAS-acting agents may not be required in Denmark at this point.
Original language | English |
---|---|
Journal | British Journal of Clinical Pharmacology |
Volume | 88 |
Issue number | 3 |
Pages (from-to) | 1379-1384 |
ISSN | 1365-2125 |
DOIs | |
Publication status | Published - 2022 |
- ACE inhibitors, angiotensin II receptor blockers, drug safety, drug utilisation, pharmacovigilance, Renin angiotensin system, risk management
Research areas
Number of downloads are based on statistics from Google Scholar and www.ku.dk
No data available
ID: 279716358